Philipp D. le Coutre

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 841 citations · Full text

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2018 · 572 citations · Full text

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla et al. · Blood · 2010 · 376 citations · Full text

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus, Tamás Masszi, Francis J. Giles et al. · Leukemia · 2017 · 286 citations · Full text

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Francis J. Giles, Philipp D. le Coutre, Javier Pinilla‐Ibarz et al. · Leukemia · 2012 · 246 citations

Chronic Phase, Hematological Malignancy, Chronic Myeloid Leukemia +6